Atovaquone for treatment of COVID-19: A prospective randomized, double-blind, placebo-controlled clinical trial.
Saved in:
| Title: | Atovaquone for treatment of COVID-19: A prospective randomized, double-blind, placebo-controlled clinical trial. |
|---|---|
| Authors: | Jain MK; Department of Internal Medicine/Infectious Diseases, University of Texas Southwestern Medical Center, Dallas, TX, United States.; Parkland Health and Hospital System, Dallas, TX, United States., De Lemos JA; Parkland Health and Hospital System, Dallas, TX, United States.; Department of Internal Medicine/Cardiology, University of Texas Southwestern Medical Center, Dallas, TX, United States., McGuire DK; Parkland Health and Hospital System, Dallas, TX, United States.; Department of Internal Medicine/Cardiology, University of Texas Southwestern Medical Center, Dallas, TX, United States., Ayers C; Department of Internal Medicine/Cardiology, University of Texas Southwestern Medical Center, Dallas, TX, United States., Eitson JL; Department of Microbiology, University of Texas Southwestern Medical Center, Dallas, TX, United States., Sanchez CL; Department of Internal Medicine/Infectious Diseases, University of Texas Southwestern Medical Center, Dallas, TX, United States., Kamel D; Department of Internal Medicine/Infectious Diseases, University of Texas Southwestern Medical Center, Dallas, TX, United States., Meisner JA; Department of Internal Medicine/Infectious Diseases, University of Pennsylvania, Philadelphia, PA, United States., Thomas EV; Department of Internal Medicine/Hospital Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States., Hegde AA; Parkland Health and Hospital System, Dallas, TX, United States.; Department of Internal Medicine/Hospital Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States., Mocherla S; Department of Internal Medicine/Infectious Diseases, University of Texas Southwestern Medical Center, Dallas, TX, United States.; Parkland Health and Hospital System, Dallas, TX, United States., Strebe JK; Parkland Health and Hospital System, Dallas, TX, United States., Li X; Department of Population and Data Science, University of Texas Southwestern Medical Center, Dallas, TX, United States., Williams NS; Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX, United States., Xing C; McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, TX, United States., Ahmed MS; Department of Internal Medicine/Cardiology, University of Texas Southwestern Medical Center, Dallas, TX, United States., Wang P; Department of Internal Medicine/Cardiology, University of Texas Southwestern Medical Center, Dallas, TX, United States., Sadek HA; Department of Internal Medicine/Infectious Diseases, University of Texas Southwestern Medical Center, Dallas, TX, United States.; Departments Biophysics, and Molecular Biology, and Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States., Schoggins JW; Department of Microbiology, University of Texas Southwestern Medical Center, Dallas, TX, United States. |
| Source: | Frontiers in pharmacology [Front Pharmacol] 2022 Sep 30; Vol. 13, pp. 1020123. Date of Electronic Publication: 2022 Sep 30 (Print Publication: 2022). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
